VAC 2025 PROGRAM
|
Day 1 │Tuesday 11 February |
|
|
12.00 – 13.00 |
Registration |
|
OPENING |
|
|
13.00 – 13.15 |
Welcome Miikka Vikkula │ Chair of the scientific
committee |
|
13.15 – 13.20 |
EPAs – Patient representatives’ message (Petra Borgards) |
|
13.20 – 13.30 |
Patient
testimonies 1 and 2. Living with visible condition (by HEVAS) |
|
KEYNOTE LECTURE |
|
|
13.30 – 14.10 |
RNA sequencing:
What have we learned and where next? Christer
Betsholtz │ Department of Immunology, Genetics and
Pathology (IGP), Uppsala University & Department of Medicine Huddinge (MedH), Karolinska Institutet,
Sweden |
|
SESSION 1 VENOUS MALFORMATIONS |
|
|
14.10 – 14.20 |
Patient testimony
3. VM (by HEVAS) |
|
14.20 – 14.50 |
Modulation of
Endothelial-specific pathways by activation of Angiopoietin-Tie2 signaling
involved in venous malformations Susan
Quaggin│ Northwestern
University Feinberg School of Medicine, Chicago, USA |
|
14.50 – 15.05 |
Short talk: In-vivo investigation of the
mechanisms driving venous malformation downstream of mutant TIE2 | Lindsay Bischoff |
|
15.05 – 15.20 |
Short talk: Exploring the role of PIK3CA
variants in vascular malformations: A combined molecular and experimental
modeling strategy | Ana
Angulo-Urarte |
|
15.20 – 15.50 |
New insights into
PI3K signaling and the consequences of genetic PIK3CA activation Ralitsa
Madsen │ School
of Life Sciences, University of Dundee, Dundee, UK |
|
15.50 – 16.30 |
Coffee break
|
|
16.30 – 16.45 |
Short talk: New promising ways for sirolimus
treatment: from continuous to intermittent administration of sirolimus in
slow-flow vascular malformations | Emmanuel Seront |
|
16.45 – 17.15 |
Venous
malformations and identifying the patient at risk for thrombosis: what do we
have? Maroeska te
Loo │ Amalia Childrens
Hospital Nijmegen and University Hospital Nijmegen, Radboudumc,
Department of Pediatrics, The Netherlands |
|
SESSION 2 VASCULAR TUMORS / HEMANGIOMAS |
|
|
17.15 – 17.45 |
Transposon
Mutagenesis Screen for Identification of Causative Genes in Vascular
Malformations Luisa
Iruela-Arispe │ Department of Cell and Developmental Biology,
Feinberg School of Medicine, Northwestern University, Chicago, USA |
|
17.45 – 18.00 |
Short talk: Discovering a pioneering function
for SOX18 in Kaposi's sarcoma, an endothelial cancer | Krista Tuohinto |
|
18.00 – 18.15 |
Short talk: Identification of a de novo
activating variant in GABPα in a patient with multiple vascular tumors of an
unclassified entity| Annegret
Holm |
|
POSTER TEASERS |
|
|
18.15 – 18.40 |
Poster teasers (5
minutes each) Annegret
Holm · Maya Alvarez-Harmon · Emmanuel
Seront · Johanna
Laakkonen · Marle Kraft |
|
WELCOME DRINK |
|
|
18.40 – 20.00 |
Networking drink |
|
Day 2 │Wednesday 12 February |
|
|
KEYNOTE LECTURE |
|
|
8.45 – 9.25 |
PROTACs, a New
Modality in Drug Discovery Enabling Highly Selective Target Degradation Stefan
Knapp │ Goethe
University Frankfurt, Frankfurt am Main, Germany Vascular single-cell |
|
SESSION 3 CAPILLARY MALFORMATIONS - STURGE WEBER
SYNDROME |
|
|
9.25 – 9.35 |
Patient testimony 4: SWS (by CMTC) |
|
9.35 – 10.05 |
Exploring the developmental biology of vascular and lymphatic
anomalies in zebrafish Nathan
Lawson│ Department of Molecular, Cell, and
Cancer Biology, University of Massachusetts Medical School, Worcester, USA |
|
10.05 – 10.20 |
Short talk: Murine endothelial expression of
GNAQ p.R183Q causes vascular malformations: trametinib does not prevent
progression of intestinal lesions | Patrick Smits |
|
10.20 – 10.50 |
Gaq[R183Q]-induced endothelial
dynamics Stephan
Huveneers │ Amsterdam UMC, University of Amsterdam,
The Netherlands |
|
10.50 – 11.30 |
Coffee break |
|
11.30 – 11.45 |
Short talk: Unraveling the mechanisms driving
vascular anomalies and associated coagulopathies in a mouse model of
hyperactive gnaq signaling | Sandra Schrenk |
|
POSTER TEASERS |
|
|
11.45 – 12.15 |
Poster teasers (5 minutes each) Sana Nasim · Mana Alaviuon · Camilo Alarcón-Pérez · Héloïse Poullet · Antonio Queiro Palou · Sabine Bailly |
|
12.15 – 13.15 |
Lunch |
|
POSTER SESSION |
|
|
13.15 – 15.15 |
Poster session 1 |
|
SESSION 4 COMPLEX LYMPHATIC ANOMALIES (CLA) AND LYMPHATIC
MALFORMATIONS (LM) |
|
|
15.15 – 15.25 |
Patient Testimony 5. Meet Becca and Libby (by
LGDA) |
|
15.25 – 15.55 |
Defining the
mechanisms by which MDFIC variants cause Central Conducting Lymphatic Anomaly Natasha
Harvey │ University
of South Australia and SA Pathology, Adelaide, Australia |
|
15.55 – 16.10 |
Short talk: A single-cell atlas of normal and
KRASG12D-malformed lymphatic vessels | Michael Dellinger |
|
16.10 – 16.25 |
Short talk: Real-world experience using alpelisib in 26 vascular anomaly patients treated at a
single institution | Whitney
Eng |
|
16.25 – 16.55 |
Coffee break |
|
16.55 – 17.25 |
A
zebrafish-based high-throughput screen identifies new candidate
treatments for KLA Karina
Yaniv │ Weizmann Institute of Science,
Rehovot, Israel |
|
17.25 – 17.55 |
Integrative
Diagnostic Imaging of Tissue Biopsies for Spatial Deep-phenotyping
of Vascular Anomalies René
Hägerling │ Institute of Medical and Human Genetics, Charité -
Universitätsmedizin Berlin and Berlin Institute of
Health at Charité, Germany |
|
17.55 – 18.10 |
Short talk: Improving targeted therapies in
complex lymphatic anomaly: two cases of synergistic efficacy of trametinib
and sirolimus | Emmanuel Seront |
|
18.10 – 18.25 |
Short talk: Propranolol Treatment in
Chylothorax: In Search of a Mechanism | June Wu |
|
Day 3 │Thursday 13 February |
|
|
8.00 – 8.45 |
Meet the speakers
(during breakfast) |
|
KEYNOTE LECTURE |
|
|
9.00 – 9.40 |
The PI3-Kinase and
AKT Pathway in Health and Disease: from Mechanisms to Therapeutics Alex
Toker │ Beth
Israel Deaconess Medical Center, Harvard Medical
School, Boston, USA |
|
SESSION 5 ARTERIO-VENOUS MALFORMATIONS |
|
|
9.40 – 9.50 |
Testimony 6. CORALINE-AVM (VASCAPA) |
|
9.50 – 10.20 |
Integrative
genomics of congenital cerebral fast-flow vascular lesions Kristopher
T. Kahle │ Harvard Medical School &
Massachusetts General Hospital, Boston, USA |
|
10.20 – 10.35 |
Short talk: Reversal of vein of Galen
aneurysmal malformation by stimulation of flow-mediated vessel fusion | Nicolas Baeyens |
|
10.35 – 10.50 |
Short talk: Formation of Human Arteriovenous
Malformation Organoid and Its Characteristics | Ho Yun Chung |
|
10.50 – 11.30 |
Coffee break |
|
11.30 – 11.35 |
Short talk: Somatic KRAS variants in limb
overgrowth with capillary malformation and fastflow,
with or without slow-flow lesions: a distinct entity named KROS | Julien Coulie |
|
11.35 – 12.05 |
Clinical use of
medicines in fast-flow vascular malformations Laurence Boon │ Saint-Luc University Clinics Vascular Malformation Centre, Brussels, Belgium |
|
POSTER TEASERS |
|
|
12.05 – 12.30 |
Poster teasers (5 minutes each) Janne de Jong · Miguel Lopez-Ramirez · Favour Onyeogaziri · Apeksha Shapeti · Konstantin Gängel |
|
12.30 – 13.15 |
Lunch |
|
POSTER SESSION |
|
|
13.15 – 15.15 |
Poster session 2 |
|
SESSION 6 HEREDITARY HAEMORRHAGIC TELANGIECTASIA (HHT) |
|
|
15.15 – 15.45 |
New understanding
in hereditary haemorrhagic telangiectasia Claire
Shovlin │ Imperial College London, UK |
|
15.45 – 16.15 |
BMP9 signaling in
safeguarding vascular integrity Roxana
Ola │ Medical Faculty Mannheim,
Heidelberg University, Germany |
|
16.15 – 16.55 |
Coffee break |
|
16.55 – 17.10 |
Short talk: Exploring vascular heterogeneity
in HHT2 brain AVM model | Alexandre
Dubrac |
|
17.10 – 17.40 |
BMP signalling in Hereditary Haemorrhagic
Telangiectasia (HHT) Petra Knaus │ Freie Universität Berlin,
Germany |
|
|
Short talk: Targeting the Root Cause of
Disease with Bispecific Agonist Antibodies | Andy Sullivan |
|
VAC NETWORKING DINNER WITH DANCE (Separate ticket) |
|
|
From 19.00 |
VAC networking
dinner with dance (separate ticket) |
|
Day 4 │Friday 14 February |
|
|
KEYNOTE LECTURE |
|
|
9.00 – 9.40 |
Phakomatosis Pigmentovascularis Veronica
Kinsler │Great Ormond St Hospital for
Children and UCL GOS Institute of Child Health & Francis Crick Institute,
London, UK |
|
SESSION 7 CEREBRAL CAVERNOUS MALFORMATIONS (CCM) |
|
|
9.40 – 9.50 |
Patient Testimony |
|
9.50 – 10.20 |
Cavernoma
profiling for biomarkers and potential treatments Peetra Magnussen │Department of
Immunology, Genetics and Pathology, Uppsala University, Sweden |
|
10.20 – 10.35 |
Short talk: Metabolic rewiring and resilience
of Cerebral Cavernous Malformations | Marco Castro |
|
10.35 – 10.50 |
Short talk: High Throughput Compound Screen
Reveals a Novel Pharmacological Agent for the Treatment of Cerebral Cavernous
Malformation | Max Arce |
|
10.50 – 11.20 |
Coffee break |
|
11.20 – 11.50 |
Germline and
somatic mutations fuel the growth of vascular malformations Doug
Marchuk │ Duke
University School of Medicine, Durham, USA |
|
SESSION 8 VASCULAR ANOMALIES |
|
|
11.50 – 12.05 |
(Sponsored
| PTEN Research
Foundation) Short talk: Somatic uniparental disomy of PTEN in endothelial cells causes congenital
vascular malformations in PTEN Hamartoma Tumor Syndrome (PHTS) patients
| Sandra Castillo |
|
12.05 – 12.20 |
Short talk: A new and optimized coding system
for vascular anomalies | Friedrich Kapp |
|
12.20 – 12.35 |
Short talk: Dual non-allelic activating
somatic oncogene variants in cutaneous vascular malformations | Pierre Vabres |
|
12.35 – 12.50 |
Short talk: Assessment of gene–disease
associations and recommendations for genetic testing for somatic variants in
vascular anomalies by VASCERN-VASCA | Nicole Revencu |
|
12.50 – 13.20 |
Awards & Closing |